



Peritoneal Carcinomatosis: Current Treatment and Future Options

Guest Editors:

**Dr. Jorge Pedro Martins
Nogueiro**

Department of General Surgery,
São João University Hospital
Center, Porto, Portugal

Dr. Hugo Santos-Sousa

1. Integrated Obesity Center (CRI-
O) & Center of Excellence in
Obesity (CED-O), São João
University Hospital Center
(CHUSJ), Porto, Portugal
2. Faculty of Medicine, University
of Porto (FMUP), Porto, Portugal
3. Obesity Clinic, Casa de Saúde
da Boavista (CSB), Porto,
Portugal

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

In the past, peritoneal carcinomatosis (PC) was considered a terminal disease only approached with palliative care and, despite the advent of new chemotherapies, with noticeable improvements in the survival of patients with metastatic cancers from multiple origins, PC still remains a devastating disease. With a reduced response to systemic chemotherapy compared to other metastatic sites, there is a progressively growing interest in the surgical approach to PC with CRS-HIPEC, and more recently, PIPAC, an alternative method to intra-peritoneal drug delivery with improved distribution and tissue uptake and better tolerance.

Patient selection, preoperative optimization, and postoperative care are of paramount importance, as much as the primary disease and treatment performed.

We aim to provide insight into the approach to peritoneal carcinomatosis, with emphasis on the new developments of multimodality treatment and surgical options, fast postoperative recovery programs, preoperative prognostic factors, and other data, aiming to improve the outcome of patients with PC.

Dr. Jorge Pedro Martins Nogueiro

Dr. Hugo Santos-Sousa

Guest Editors





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and
Critical Care Medicine, University
of Tokyo, Tokyo 113-8655, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) / CiteScore - Q1 (*General Medicine*)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)